Anna I. Prokaeva

Anna I. Prokaeva

Auto-generated profile, based on publicly available information

Anna I. Prokaeva

International Tomography Center, Siberian Branch of the Russian Academy of Sciences

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2024 in Siberian Scientific Medical Journal
Verified
Journal Article
Open access
PDF file
APA. I. Prokaeva
A. I. Prokaeva
IAI. E. Arkhipov
I. E. Arkhipov
EDE. E. Dorchinets
E. E. Dorchinets
DKDenis Korobko
Denis Korobko
NMN. A. Malkova
N. A. Malkova
Multiple sclerosis (MS) is one of the most common causes of disability in young people of working age. The prevalence of this disease has increased significantly in recent years and today amounts to more than 2 900 000 people worldwide. The transition from relapsing-remitting MS to secondary progressive MS is observed in 25 % of cases within 10 years the disease duration, and with further time the proportion of patients with secondary progressive MS increases. Despite the importance of preventing patient disability, today the diagnosis of secondary progressive MS is established retrospectively, which makes the issue of identifying early markers of disease progression extremely relevant. The most promising diagnostic markers allow the differentiation of progressive MS with a sensitivity of up to 87 % and a specificity of up to 90 %. This review will consider the most promising clinical, instrumental and biological signs of early progression of MS.

29 December 2023 in Russian Ophthalmological Journal
Verified
Journal Article
Open access
PDF file
AFA. Zh. Fursova
A. Zh. Fursova
MZM. Yu. Zubkova
M. Yu. Zubkova
MVM. A. Vasilyeva
M. A. Vasilyeva
YGYu. A. Gamza
Yu. A. Gamza
NMN. A. Malkova
N. A. Malkova
FRF. K. Rabota
F. K. Rabota
Purpose: to study significant functional and structural changes in the retina and the intraocular section of the optic nerve in multiple sclerosis (MS) patients and analyze how they are interrelated with electrophysiological changes in the visual analyzer.Materials and methods. The study included 44 patients (88 eyes): group 1 (26 eyes) with MS duration ≤ 5 years and no history of optic neuritis (ON); group 2 (30 eyes) with MS duration from 6 to15 years and no history of ON; and group 3 (32 eyes) with MS duration ≤ 15 years with a history of ON. All patients underwent a complete ophthalmological examination and optical coherence tomography and had visually evoked potentials (VEP) and static automated perimetry registered.Results. A decrease in functional and structural parameters progressing with the duration of MS was revealed. In particular, best corrected visual acuity (BCVA) fell to 0.860 ± 0.075, the photosensitivity index MD maximally fell to -3.78 ± 0.95 dB, the strength of the P100 wave amplitude dropped to 7.84 ± 2.98 μV, the latency index of VEP rose to 124.21 ± 1.36 ms, the thickness of GCL + IPL fell to 65.69 ± 7.85 μm, and RNFL thickness averagely fell a low as to 80.25 ± 8.81 μm. When analyzing the topography of GCL + IPL decrease by sectors, the maximum value was revealed in the upper temporal segment (67.63 ± 7.89 μm). Sectoral changes in RNFL arranged in descending order of thickness showed the following sequence: lower upper nasal temporal. As the disease progressed, structural and functional changes were accompanied by an increase in the depth and a decrease in the thickness of the lamina cribrosa, with a maximum value revealed in the group with prior ON (239.00 ± 11.93 μm). Strong correlations were found in all study groups between (1) ave. GCL + IPL and ave. RNFL (r = 0.69; 0.64; 0.88, p < 0.03), (2) ave. GCL+IPL and BCVA (r = 0.86; 0.75; 0.78, p < 0.05), (3) MD and ave GCL + IPL (r = 0.52; 0.69; 0.71, p < 0.03), and (4) MD and ave. RNFL (r = 0.67; 0.61; 0.66, p < 0.05), as well as between the parameters of the lamina cribrosa and the markers under study.Conclusion. Significant functional and structural changes in the retina and the optic nerve were detected, correlating with the duration of the disease and with the clinical features of the course of multiple sclerosis. The presence of ON in history was accompanied by more pronounced changes, which can be considered as an important additional aggravating factor of the disease.

17 July 2023 in Consilium Medicum
Verified
Journal Article
Open access
PDF file
DKDenis Korobko
Denis Korobko
IAIvan Ie. Arkhipov
Ivan Ie. Arkhipov
APAnna I. Prokaeva
Anna I. Prokaeva
ETEkaterina V. Tret'IAkova
Ekaterina V. Tret'IAkova
АЕАрхипов Иван Евгеньевич
Архипов Иван Евгеньевич
Siponimod (Kajendra) is a sphingosine-1-phosphate receptor modulator type 1 and 5 (S1P1,5), the first targeted agent for the treatment of patients with secondary progressive multiple sclerosis, both with and without exacerbations and/or activity according to magnetic resonance imaging. The drug was approved in Russia at the end of December 2020. The efficacy of siponimod was confirmed in EXPAND study, a large, randomized, double-blind phase III clinical study. This article presents three clinical cases of patients with secondary progressive multiple sclerosis from the practice of specialists of the Novosibirsk Center for Multiple Sclerosis and Other Autoimmune Diseases of the Nervous System with an analysis of patients selection for siponimod treatment and an assessment of the therapy effectiveness.

11 February 2025 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
IAI.E. Arkhipov
I.E. Arkhipov
APA.I. Prokaeva
A.I. Prokaeva
ETE.V. Tretyakova
E.V. Tretyakova
DKDenis Korobko
Denis Korobko
NMN.A. Malkova
N.A. Malkova
Objective. To study the dynamics of the epidemiological characteristics of multiple sclerosis (MS) from 01.01.2003 to 01.01.2024 in Novosibirsk in comparison with the previous 20-year study. Material and methods. The prevalence cohort included 2254 patients with MS living in Novosibirsk on 01.01.2024. The cohort of cases included 1998 patients with the onset of the disease from 01.01.2003 to 31.12.2023 inclusive. In order to level out the influence of heterogeneous sex and age composition of the population of Novosibirsk, the method of standardization of indicators was used in the study (standard European population, 13.07.2013). The results of our analysis were compared with the results of the previous epidemiological study in the city of Novosibirsk (Malkova N.A., 2005). Results. The prevalence of MS as of 01.01.2024 was calculated as 137.83 per 100 thousand population (standardized indicator — 123.43). The average age of the patients with MS was 46.146±0.479 years. The ratio of men to women was 1:2.1. The incidence of MS from 2003 to 2023 shows a trend toward an increase (5.12±0.0662 to 7.71±0.0246 per 100 thousand population/year (p<0.05), which is mainly due to a significant increase in the proportion of women (6.56±0.1118 to 11.01±0.091 per 100 thousand population/year, p0.05). The average age of MS onset increased by 0.146 years annually during the study period and amounted to 30.479±0.329 years (rxy=0.08, p<0.001). An increase in the incidence of early-onset and late-onset MS was also noted (rxy=0.45, p=0.041 and rxy=0.622, p=0.003, respectively). A significant decrease in the «onset—diagnosis» interval was recorded (mean 5.28±6.41 years on 01.01.2003; mean 1.77±0.921 years on 01.01.2024). Conclusions. In the era of controlled disease progression, our study showed an increase in the prevalence of MS from 2003 to 2023 (54.4 to 137.83 per 100 thousand population). The dynamics of the sex ratio of patients with MS in Novosibirsk does not demonstrate the global trend with a 3—4-fold increase in the proportion of women. An increase in the incidence of MS was noted from 2003 to 2023 (p<0.05), mainly due to women (p<0.05). The age of MS onset has increased significantly over the 20-year period (27.73±0.6 years in 2003; 30.479±0.329 years in 2023). A separate trend towards an increase in the incidence of early-onset and late-onset MS is shown (rxy=0.45, p=0.041 and rxy=0.622, p=0.003, respectively). In part, the increase in the epidemiological characteristics of MS is associated with a decrease in the «onset—diagnosis» interval (p<0.05), which is due to improved diagnostic criteria and health care services.

1 January 2025 in JOURNAL of SIBERIAN MEDICAL SCIENCES
Verified
Journal Article
Closed access
NHNovosibirsk State Novosibirsk Regional Clinical Hospital
Novosibirsk State Novosibirsk Regional Clinical Hospital
IAI.E. Arkhipov
I.E. Arkhipov
APA.I. Prokaeva
A.I. Prokaeva
DKDenis Korobko
Denis Korobko
NMN.A. Malkova
N.A. Malkova
Introduction. Multiple sclerosis (MS) is a major cause of disability among young people after traumatic injuries. Many studies indicate changes in the clinical picture of MS over time, which is partly attributed to the use of pathogenetic therapy. Aim. To study the changes in the clinical picture of MS between 01.01.2003 and 31.12.2022 in Novosibirsk. Materials and methods. 1783 patients with MS diagnosed in the period from 01.01.2003 to 31.12.2022, who lived in Novosibirsk, were included in the study. The clinical picture was described (symptoms grouped by functional systems of the Kurtzke Expanded Disability Status Scale (EDSS)); besides, the MS phenotype, EEDSS score, and whether MS disease-modifying therapies (MSDMTs) were prescribed indicating their duration, were determined. The number of symptoms at the onset (mono- and polysymptomatic) and the grade of recovery of neurological disorders were assessed. The achievement of EDSS 3,0 and EDSS 6,0 in the group of “controlled” MS was also analyzed, considering the following indices: duration of the disease (time from the onset of the clinical phase of MS to 12.31.2022), the interval “onset – EDSS 3,0”, the interval “onset – EDSS 6,0”. This group included 1494 patients who met two criteria: MSDMTs for at least 6 months, and the duration of the MS clinical phase for at least 2 years. Results. Pathogenetic therapy of MS changed the course of the disease. The clinical picture of MS was characterized by an increase in the proportion of patients with a remitting course (from 52 to 75%, p < 0,05). The role of the gender of patients in achieving permanent disability has decreased. The onset symptoms were found to be of great importance in the long-term prognosis of persistent disability (p < 0,05). Conclusion. Gender, age, symptoms at the MS onset, and the use of pathogenetic therapy correlate with the risk and likelihood of achieving permanent disability (p < 0,05).

28 June 2024 in Russian Ophthalmological Journal
Verified
Journal Article
Closed access
AFA. Zh. Fursova
A. Zh. Fursova
MZM. Y. Zubkova
M. Y. Zubkova
MVM. A. Vasilyeva
M. A. Vasilyeva
YGY. A. Gamza
Y. A. Gamza
ADA. S. Derbeneva
A. S. Derbeneva
PPP. N. Pozdnyakova
P. N. Pozdnyakova
Purpose: to identify the intraretinal hyperreflective foci (HRF), their specific characteristics, localization features and correlations with the duration of the disease, type of course and previous episodes of optic neuritis (ON) in multiple sclerosis (MS) patients using a high-resolution OCT scanning protocol. Materials and methods. The study included 160 patients (318 eyes) divided into 8 groups, i.e. Group 1: 44 eyes (13.84 %) — MS onset without a history of ON; Group 2: 30 eyes (9.43 %) — debut of MS with ON; Group 3: 56 eyes (17.61 %) — relapsing-remitting MS (RRMS) lasting ≤ 10 years without ON; Group 4: 38 eyes (11.95 %) — RRMS lasting ≤ 10 years with ON; Group 5: 49 eyes (15.41 %) — RRMS lasting ˃ 10 years without ON; Group 6: 37 eyes (11.63 %) — RRMS lasting ˃ 10 years with ON; Group 7: 34 eyes (10.69 %) — secondary progressive MS (SPMS) without ON; Group 8: 30 eyes (9.43 %) — SPMS with ON. Results. HRF were identified in all groups, at the levels of both the outer nuclear layer (ONL) and the inner nuclear layer (INL). Their number increased depending on the duration, type of course, and the presence of ON history. The thickness of the inner layers of the retina corresponded to the average normative indicators in the group with the onset of MS without ON. In the SPMS group after ON, a decrease in the total thickness of ganglions retinal cells layer (GCL) and the inner plexiform layer (IPL) was noted, showing minimal values of both avGCL + IPL (65.83 ± 8.27 μm) and avRNFL (76.37 ± 6.94 μm). High inverse correlations were revealed between avGCL + IPL and the amount of GRF at the levels of ONL and INL (-0.82 and -0.85, respectively, p = 0.01). Conclusions. The presence and quantity of HRF can be considered as a prognostic non-invasive biomarker associated with the duration of MS and the history of ON, allowing one to visualize the penetration of microglia activated by immune cells into the unmyelinated part of the central nervous system, helpful in elucidating their role in the pathogenesis and progression of the disease.